Table 3: Patients characteristics with respect to the detected associations with the VEGF T and bFGF G variants in comparison with healthy population. The bFGF G variant was more frequently detected among patients with aggressive histological subtype of NHL. The VEGF T variant was more frequently detected among patients presented with high IPI. Individuals carrying the VEGF T variant are over three times more likely to develop NHL characterized by the highest IPI score, while those with the bFGF G allele are over twice more likely to present with aggressive histological type of the disease.

NHL patients VEGF pp. 936 bFGF pp. −921
CC T CC G
(%) (%) (%) (%)

IPI risk groups
Low/intermediate low (1, 2)4035
(87.5%)
5
(12.5%)
31
(77.5%)
9
(22.5%)
Intermediate high/high (3, 4)3826
(68.4%)
12
(31.6%)
26
(68.4%)
12
(31.6%)
Low/intermediate (1–3)6151
(83.6%)
10#
(16.4%)
46
(75.4%)
15
(24.6%)
High (4)1710
(59%)
7#,**
(41%)
11
(64.7%)
6
(35.3%)

Histological aggressiveness
Indolent4031
(77.5%)
9
(22.5%)
33
(82.5%)
7
(17.7%)
Aggressive3830
(78.9%)
8
(21.1%)
24
(63.2%)
14†,‡
(36.8%)
Patients7861
(78.2%)
17
(21.8%)
57
(73%)
21* 
(27%)
Healthy individuals122101
(82.8%)
21
(17.2%)
99
(81.1%)
23*,‡
(18.9%)

NHL: non-Hodgkin's lymphoma; IPI: International Prognostic Index; *(NHL patients versus controls) OR = 1.61, ; (patients with aggressive versus patients with indolent disease) ; (patients with aggressive disease versus controls) OR = 2.51, ; (patients with intermediate high/high IPI (3, 4) versus low/intermediate low IPI (1, 2)) ; (patients with intermediate high/high IPI (3, 4) versus controls) OR = 2.22, ; #(patients with high (4) versus low/intermediate (1–3) IPI) ; **(patients with high IPI (4) versus controls) OR = 3.37, .